anticancer drug stanford synchrotron radiation lightsource stanford synchrotron radiation lightsource an office of science user facility home anticancer drug structural insights into the action of new anti cancer drugs structural insights into the action of new anti cancer drugs june 16 2011 3 29pm admin the photon science seminar series brings together researchers and engineers from all areas of the photon sciences to stimulate scientific exchange and make people aware of both the science that's underway using the ssrl and lcls machines and the capabilities they offer the seminars take place every wednesday at 3 00 pm in slac's building 901 redtail hawk conference room structural insights into the action of new anti cancer drugs date time june 22 2011 3 00 pm location slac redtail hawk conference room 108a speaker dong wang ucsd speaker biography dr wang's research focuses on understanding the mechanisms of cellular responses to dna damage specifically the goals of dr wang's research are 1 to understand how dna damage is recognized during transcription 2 to elucidate the structural basis of dna damage processing pathways and 3 to pave the way for rational improvement of novel anticancer drugs tags anticancer drug cancer cisplatin abstract cancer is a group of common diseases characterized by the uncontrolled growth and invasion of normal tissues over 1.5 million new cancer patients are diagnosed and 0.5 million people die of cancer each year in the united states the chemotherapy drug cisplatin represents a major landmark in the history of successful anti cancer drugs however acquired or intrinsic drug resistance to cisplatin limits its implication in chemotherapy novel anti cancer drugs are needed to overcome the drug resistance in this talk dong wang will present recent research progress toward understanding the structural basis of action of a novel anti cancer compound and knowledge that could inform future drug design potential anti cancer drug has novel mechanism of action 2011 peeking inside a polymerase trap read more easy to get in hard to get out x ray structure and mechanism of rna polymerase ii stalled at an antineoplastic monofunctional platinum dna adduct posted 2011 dna is a major target of anticancer drugs the resulting adducts interfere with transcription and other key cellular processes and trigger downstream events responsible for drug activity pyriplatin cis diammine pyridine chloroplatinum ii is a monofunctional platinum ii analogue of the widely used anticancer drug cisplatin the novel structure activity properties of pyriplatin hold promise for overcoming drug resistance and improving the spectrum of treatable cancers over those responsive to cisplatin however the detailed molecular mechanism by which cells process pyriplatin damaged dna is not fully understood here we report the structure of a transcribing rna polymerase ii pol ii complex stalled at a site specific pyriplatin dna adduct the results suggest a molecular mechanism of pol ii transcription inhibition and drug action that is dramatically different from transcription inhibition by cisplatin and uv induced 1 2 intrastrand cross links our findings provide insight into structure activity relationships that may apply to the entire family of monofunctional dna damaging agents and pave the way for the rational design of novel anticancer drugs read more syndicate content the stanford synchrotron radiation lightsource is a directorate of slac national accelerator laboratory which is operated by stanford university for the department of energy other news sources slac today ssrl headlines symmetry magazine lightsources org interactions org ilc newsline spires slac national accelerator laboratory slac national accelerator laboratory menlo park ca operated by stanford university for the us department of energy office of science content owner cathy knotts privacy notice security notice and terms of use doe stanford university
